Text Size

Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study

Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D


  • 2023
  • Asia Pac J Ophthalmol (Phila)
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Clinical development

  • Affiliations

    Singapore National Eye Centre, Singapore, Singapore; Department of Ophthalmology, National University Hospital, Singapore, Singapore; Santen Canada Inc., Toronto, ON, Canada; Santen Pharmaceuticals Co. Ltd, Osaka, Japan; Eye and Retina Surgeons, Camden Medical Center, Singapore, Singapore

Related Publications

Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.


Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase 2/3 ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y. on behalf of the ORANGE study investigators


Epidemiology and burden of mild/moderate versus high myopia in Germany: A claims data analysis

Garcia TB, Kossack N, Pignot M, Dagher M, Schuster AK, Wielink KS.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022